Simple biological age score flags higher cognitive decline risk in older adults

By Dr. Priyom Bose, Ph.D.Reviewed by Lauren HardakerAug 10 2026

A biological age score calculated from just four routinely available measures was linked to future cognitive problems, suggesting that how the body ages may reveal risks that chronological age alone can miss.

Study: Association between light BioAge and cognitive impairment risk in middle-aged and elderly people: a retrospective cohort study. Image Credit: Lightspring

A recent study published in the journal Scientific Reports examined the relationship between light BioAge and the risk of cognitive impairment and cognitive decline in middle-aged and older adults, utilizing data from a large Chinese longitudinal cohort.

Cognitive Impairment and Biological Aging

Cognitive impairment describes a decline in mental abilities, including memory, reasoning, attention, and language, which goes beyond typical age-related changes. It is prevalent in older adults and can range from mild deficits to severe loss of independence, with dementia representing the most severe and disabling manifestation.

Mild cognitive impairment affects approximately 15.6% of community-dwelling adults aged 50 years and older worldwide, while prevalence in China has been estimated at 19.6%. Its effects extend beyond cognition, impacting psychological well-being, social participation, physical function, and contributing to a substantial economic burden.

Age is the primary risk factor, but others include cardiovascular diseases, hypertension, obesity, diabetes, smoking, depression, physical inactivity, and low educational level. Aging triggers changes in the brain, including hippocampal atrophy, imbalance in amyloid beta, increased inflammation, and neuronal vulnerability in memory-related areas, which may contribute to cognitive impairment.

However, individuals age at different rates, and chronological age does not always reflect true biological aging. Several biological aging models have been developed, such as DNA methylation clocks and organ-specific aging measures, but these often require complex biomarkers and calculations, limiting their practical use.

A simplified biological aging index, termed light BioAge, was recently developed. It incorporates four metrics: chronological age, creatinine, blood glucose, and C-reactive protein (CRP). This index is straightforward to calculate and demonstrates strong associations with mortality and frailty. However, the relationship between light BioAge and the risk of cognitive impairment has not been clearly established.

Examining Light BioAge and Cognitive Outcomes in a Chinese Cohort

Scientists assessed associations between light BioAge and cognitive outcomes using data from the China Health and Retirement Longitudinal Study (CHARLS), a nationally representative cohort of Chinese adults aged 45 and older spanning 2011–2020. CHARLS collected detailed information on health, socioeconomic status, and pension security.

CHARLS used a multistage, stratified, cluster-randomized design to recruit approximately 17,000 participants from 150 counties and 450 communities. Data included demographics, health status, physical activity, medical history, lifestyle, and laboratory values.

Light BioAge at baseline was the exposure variable. Baseline data were collected in 2011–2012, with follow-ups in 2013, 2015, 2018, and 2020. Only participants from 2011–2012 without baseline cognitive impairment or memory-related diseases, and with the data needed to calculate light BioAge and assess cognition during follow-up, were included.

The primary outcome was new-onset cognitive impairment during follow-up. Secondary outcomes included declines in mental intactness and episodic memory. Cognitive function was measured using a 0–31-point scale, with higher scores indicating better function. The assessment comprised two components: episodic memory (0–20 points; immediate and delayed word recall) and mental state (0–11 points; orientation, calculation, and drawing tasks). Cognitive impairment was defined as a total score below 11, while declines in mental intactness or episodic memory were defined using changes from baseline, with difference scores below the lowest quartile classified as a decline. This survey-based definition of cognitive impairment was not equivalent to a clinical diagnosis of mild cognitive impairment or dementia.

Associations between light BioAge and cognitive decline were analyzed using Cox regression, adjusting for confounders. Subgroup, non-linear, and sensitivity analyses were also performed.

Higher Light BioAge Remains Associated with Poorer Cognitive Outcomes

A total of 17,272 participants aged 45 years or older were included in the 2011-2012 CHARLS. After excluding individuals with baseline cognitive impairment, memory-related diseases, missing light BioAge data, or no cognitive assessment data during any of the four follow-up surveys, 4,818 participants were included in the analysis. During follow-up, 23.72% developed cognitive impairment, 40.70% showed a decline in mental intactness, and 35.14% experienced episodic memory decline.

Analysis revealed that higher light BioAge remained associated with increased risks of cognitive impairment, episodic memory decline, and reduced mental intactness after controlling for chronological age and other potential confounders. Because chronological age is itself a component of light BioAge, the authors cautioned that this should not be interpreted as an effect entirely independent of chronological age. Notably, individuals with light BioAge ≥56.82 years had substantially higher risks of cognitive impairment and episodic memory decline than those with light BioAge <42.45 years.

Sensitivity analyses supported these findings, indicating that higher light BioAge remained associated with poorer cognitive outcomes. No significant non-linear associations were found. Adding light BioAge to multivariable models produced small but statistically significant improvements in predictive performance across all three cognitive outcomes, while a separate analysis found that combining age with light BioAge better predicted cognitive impairment than age alone.

Exploratory subgroup analyses further suggested that the association between higher light BioAge and cognitive risks persisted across several demographic and health-related groups, although the patterns were not consistent across all subgroups. These results suggest that light BioAge may have potential as an epidemiological marker of cognitive risk, although its additional ability to distinguish individual risk appears modest.

The Potential Predictive Value of Light BioAge for Cognitive Health in Aging Adults

The current study found that higher light BioAge is associated with increased risks of cognitive impairment, episodic memory decline, and reduced mental intactness among middle-aged and older adults.

Light BioAge provided modest additional predictive information, and for cognitive impairment, combining light BioAge with chronological age performed better than age alone. It may serve as a potential epidemiological marker for the early identification of cognitive impairment risk in this population. However, the study does not establish causality, and cognitive impairment was identified using survey-based cognitive testing rather than a clinical diagnosis. 

The authors also noted potential selection bias from extensive participant exclusions and the need to validate the findings in other populations before light BioAge can be considered for routine clinical risk assessment.